CR20200287A - Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado - Google Patents

Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado

Info

Publication number
CR20200287A
CR20200287A CR20200287A CR20200287A CR20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A
Authority
CR
Costa Rica
Prior art keywords
mutated ras
restricted
hla class
cell receptors
tcr
Prior art date
Application number
CR20200287A
Other languages
English (en)
Inventor
Rami Yoseph
Yong-Chen Lu
Steven A Rosenberg
Gal Cafri
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of CR20200287A publication Critical patent/CR20200287A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses

Abstract

<p>Se describe un receptor de células T aisladas o purificadas (TCR), en donde el TCR tiene especificidad antigénica para una secuencia de aminoácidos de RAS mutado presentado por una molécula de antígeno leucocitario humano (HLA) clase I. También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos relacionados, vectores de expresión recombinante, células hospedadoras, poblaciones de células, y composiciones farmacéuticas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero</p>
CR20200287A 2017-12-04 2018-12-03 Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado CR20200287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594244P 2017-12-04 2017-12-04
PCT/US2018/063581 WO2019112941A1 (en) 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras

Publications (1)

Publication Number Publication Date
CR20200287A true CR20200287A (es) 2020-11-11

Family

ID=64949411

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200287A CR20200287A (es) 2017-12-04 2018-12-03 Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado

Country Status (15)

Country Link
US (2) US11466071B2 (es)
EP (1) EP3720478A1 (es)
JP (2) JP7385566B2 (es)
KR (1) KR20200115484A (es)
CN (1) CN111836638A (es)
AU (1) AU2018378200A1 (es)
BR (1) BR112020011111A2 (es)
CA (1) CA3084246A1 (es)
CR (1) CR20200287A (es)
EA (1) EA202091335A1 (es)
IL (1) IL275031A (es)
MA (2) MA51043A (es)
MX (1) MX2020005765A (es)
SG (1) SG11202005236QA (es)
WO (1) WO2019112941A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063905A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CA3130618A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CN115279784A (zh) * 2020-02-12 2022-11-01 美国卫生和人力服务部 针对含有g12d突变的ras的hla i类限制性t细胞受体
GB2610311A (en) * 2020-02-14 2023-03-01 Us Health HLA class I-restricted T cell receptors against RAS with G12V mutation
AU2021225872A1 (en) * 2020-02-26 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12V mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
KR102488353B1 (ko) * 2020-10-08 2023-01-12 부산대학교 산학협력단 돌연변이 kras를 표적하는 펩타이드 및 이의 용도
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
CA3219923A1 (en) * 2021-05-25 2022-12-01 Christopher A. KLEBANOFF T cell receptors targeting ras mutations and uses thereof
WO2023139257A1 (en) 2022-01-21 2023-07-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023241522A1 (zh) * 2022-06-14 2023-12-21 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CN115960204B (zh) * 2022-11-04 2023-08-25 新景智源生物科技(苏州)有限公司 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2734889T3 (es) * 2010-09-21 2019-12-12 Us Health Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US11207394B2 (en) 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
SG10201913868XA (en) * 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
KR20180089446A (ko) * 2015-12-23 2018-08-08 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
US20210052642A1 (en) * 2017-12-04 2021-02-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells

Also Published As

Publication number Publication date
US11466071B2 (en) 2022-10-11
US20230026180A1 (en) 2023-01-26
JP7385566B2 (ja) 2023-11-22
MX2020005765A (es) 2020-09-25
SG11202005236QA (en) 2020-07-29
JP2021505136A (ja) 2021-02-18
JP2023175703A (ja) 2023-12-12
CN111836638A (zh) 2020-10-27
BR112020011111A2 (pt) 2020-11-17
US20210079058A1 (en) 2021-03-18
KR20200115484A (ko) 2020-10-07
WO2019112941A1 (en) 2019-06-13
MA51043A (fr) 2020-10-14
MA51042A (fr) 2020-10-14
EP3720478A1 (en) 2020-10-14
AU2018378200A1 (en) 2020-07-02
IL275031A (en) 2020-07-30
EA202091335A1 (ru) 2020-10-15
CA3084246A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
CR20200287A (es) Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
AU2021203746B2 (en) T cell receptors recognizing MHC class II-restricted MAGE-A3
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
CR20200170A (es) Receptores de células t que reconocen p53 mutado
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
MX2022009654A (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
BR112017012484A2 (pt) vírus isolado, cultura celular, gene que codifica uma proteína, proteína, fragmento de dna, vírus de vetor recombinante vivo, pseudo-partícula, vacina, anticorpo ou antissoro, método para a preparação de uma vacina, e, kit de teste diagnóstico.
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer